Cargando…
Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
PARP inhibitors target BRCA mutations and defective homologous recombination repair (HRR) for the treatment of epithelial ovarian cancer (EOC). However, the treatment of HRR-proficient EOC with PARP inhibitors remains challenging. The objective of this study was to determine whether the combination...
Autores principales: | Lin, Z. Ping, Zhu, Yong-Lian, Lo, Ying-Chun, Moscarelli, Jake, Xiong, Amy, Korayem, Yasmin, Huang, Pamela H., Giri, Smith, LoRusso, Patricia, Ratner, Elena S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239325/ https://www.ncbi.nlm.nih.gov/pubmed/30444904 http://dx.doi.org/10.1371/journal.pone.0207399 |
Ejemplares similares
-
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without
BRCA
Mutation
por: Kim, Joseph W., et al.
Publicado: (2021) -
Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
por: Mansouri, Anita, et al.
Publicado: (2021) -
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
por: Lheureux, Stephanie, et al.
Publicado: (2023) -
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
por: Lee, Jung-Min, et al.
Publicado: (2022) -
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
por: Kim, Joseph W., et al.
Publicado: (2023)